Lung cancer "master protocol" eyed as paradigm-changing approach to drug development (Pink Sheet - Informa) - Nov 18, 2013 - "The biomarker-driven, multi-arm, multi-drug [P2/3] registration trial is expected to get under way in March 2014...four companies are supplying targeted therapies: Amgen Inc. [Rilotumumab], AstraZeneca PLC [AZD4547], Genentech Inc. [PI3 kinase inhibitor] and Pfizer Inc [Palbociclib]. AstraZeneca’s MedImmune division is providing a PD-L1 inhibitor [MEDI4736]"
Anticipated new P2/3 trial • Non Small Cell Lung Cancer • Oncology
|
|
A subscription to The Pink Sheet is required to access this article
|